Tuesday September 26 was an exciting day for the PureIMS team. Not only was the first cohort of volunteers dosed in the penultimate Levodopa Cyclops™ bioavailability study, we were also honored with the LIFE Science Innovation Award. LIFE Cooperative, very successfully organizing their annual conference and award ceremony, is a cooperation of 50+ LifeScience and MedTech SMEs […]
Following a successful funding round in April of this year (link: successful funding round), PureIMS obtained ethical approval for a pharmacokinetic dose-finding study with its dry powder inhaler lead program Levodopa Cyclops™ and expects to have the study results before the end of 2023. Earlier clinical studies already demonstrated very rapid onset of action, a […]
PureIMS today announced it has secured a new investment round. New investor Boost-UP Foundation has joined current shareholders (CardusoCapital venture capital fund, IMDS Medical Devices and LinesBridge Pharma Group) in this round to finance the company’s ambitious growth strategy. Please find the full press release via this link:
Roden — February 10, 2023 — PureIMS, a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases, has appointed Frank Lambert to the role of Executive Director Commercialization. DPI developer PureIMS has announced the appointment of Frank Lambert as Executive Director Commercialization. The appointment is part of the […]
Check out our scientific poster for DDL2022 on Epinephrine Cyclops™!
PureIMS will be present at the Drug Delivery to the Lungs Conference 2022 in Edinburgh. Please visit our stand (246) and have a chat. We will be more than happy to tell you everything about our Cyclops™ single-use dry powder inhaler and hear all about your interesting projects too! Furthermore, check out our posters on […]
Roden — January 7, 2022 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases has appointed Jaap Wieling to the role of Chief Executive Officer (CEO). Dr. Wieling brings 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research […]
Inhaled levodopa for the rescue treatment of OFF episodes in Parkinson’s disease OFF episodes are an unmet medical need with a great impact on the quality of life of Parkinson’s disease patients. Oral levodopa does not prevent the occurrence of OFF episodes, nor enables their fast resolve, mainly because of a highly variable and unreliable […]
PureIMS aims to find a partner for its lead program Levodopa Cyclops™ Roden — December 22, 2021 — PureIMS today announced that it is participating in Biotech Showcase™ 2022. PureIMS is a clinical stage pharmaceutical and medication systems company developing a portfolio of products addressing acute and unmet medical needs. These products are based on […]
PureIMS preparing for Series A financing round aiming to bring its two lead programs to marketing authorization Roden — December 16, 2020 — PureIMS today announced that it is participating in Biotech Showcase™ Digital 2021, and providing an on-demand company presentation. Bram van Dijck, CEO, will be presenting PureIMS at Biotech Showcase Digital. PureIMS is […]
Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com
